The results indicate that in venae impotence it might be useful to reduce the longitudinal strain of the tunica albuginea by ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing disease geographic atrophy ...
Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and preliminary efficacy of CTx001 as a potential one-time treatment for GA Opti-GAIN builds on insights from i-GAIN, a ...
NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.
With a maximum working pressure of 350 bar (5,000 PSI), an increase of up to 40% over the first-generation platform and with its distinctive black coating and dedicated labeling, the New MultiFaster ...
Editor’s note: This is Part 1 of a two-part series on crime solutions from Katie Hill and Jens Ludwig of the University of Chicago Crime Lab. The overheated political moment we’re in has led people to ...
The New York Rangers finished their preseason with a 4-1 loss to the Boston Bruins on Saturday, and although it's early, Mike Sullivan's team already gave signs of what it could be. The Rangers' ...
AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
A Corpus-Based Study on the Variations of Semantic Constraints over Mandarin Chinese VV Construction in Different Sentential Contexts ...
Wanna see a trick? Give us any topic and we can tie it back to the economy. At Planet Money, we explore the forces that shape our lives and bring you along for the ride. Don't just understand the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果